Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

ASCENT-03 did not demonstrate early overall survival separation because 80% of control patients crossed over to sacituzumab upon disease progression. In contrast, Tropion Breast-02 prohibited structured crossover, allowing datopotamab deruxtecan to demonstrate statistically significant improvements across both progression-free and overall survival endpoints.

Related Insights

The trial allowed patients in the placebo group to receive retifanlimab upon progression (crossover). This common design dilutes the observed overall survival difference. While initial results were not statistically significant, updated data revealed a clinically meaningful 10.6-month median OS improvement.

The Podium 303 study's design allowed placebo patients to receive retafanilumab upon progression. This crossover contaminated the control arm, likely diluting the true overall survival benefit and making the first-line combination therapy appear less statistically significant than it actually is.

In trials like ASCENT-4, where over 80% of the control arm received sacituzumab govitecan upon progression, the true overall survival (OS) benefit is obscured. This makes progression-free survival (PFS) a more reliable endpoint for evaluating the drug's first-line efficacy.

In the TROPION-Breast02 trial, a survival benefit for Dato-DXD was seen mainly in regions without later-line access to TROP2 ADCs. Western patients often received an ADC second-line, muting the first-line survival difference and showing how post-progression therapy access can confound trial results.

The AscentO3 trial lacked an overall survival benefit for its primary endpoint because its design ethically allowed patients on the chemotherapy arm to receive sacituzumab govitecan upon progression. This 'crossover' improves care for the control group but makes it statistically difficult to demonstrate a first-line survival advantage.

In pivotal ADC trials like ASCENT-03 and 04, over 80% of patients in the control (chemotherapy) arm received the ADC upon progression. This high crossover rate makes interpreting overall survival (OS) data difficult, as the control group's outcomes are artificially improved by subsequent access to the novel drug.

In the ASCENT-07 trial, investigators may have prematurely switched patients from the standard chemotherapy arm to superior, commercially available ADCs at the first hint of progression. This real-world practice can mask an experimental drug's true benefit on progression-free survival.

The ASCENT-03 trial allowed control arm patients to receive sacituzumab govitecan upon progression. This ethical choice complicates overall survival interpretation, as many control patients ultimately got the active drug, making direct comparison with non-crossover trials like TROPION-Breast02 difficult.

The trial allowed over 75% of patients in the control group to receive Rucaparib after their cancer progressed. While ethical, this high crossover rate effectively turned the study into an "upfront vs. delayed PARP inhibitor" comparison, which is the primary reason no significant overall survival difference was observed.

The ASCENT-03 and -04 trials featured a high rate of crossover, with over 80% of patients in the chemotherapy arm receiving Sacituzumab Govitecan (SG) upon progression. This ethical trial design confounds the overall survival (OS) data, making the observed OS benefit appear smaller than the drug's true potential if used exclusively in the first-line setting.

Built-In Trial Crossover Masks Overall Survival Benefits in ADC Trials | RiffOn